Gabriel Lazcano, MD
Ophthalmology · Miami, FLNPI 1699776534
Payments from drug & device makers
Across 194 payments — averaging $258.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$43K
- Biotissue Holdings Inc.$2K
- AbbVie$2K
- Alcon$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$865
- Sun Pharmaceutical Industries Inc.$309
- plus $1K from 17 others
Across 42 payments — averaging $2197.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$92K
What the payments were for
- Consulting fees$21,25742%
- Speaking & faculty fees$16,43833%
- Travel & lodging$4,97710%
- Food & beverage$7,46815%
- Gifts$170%
- Other$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 35 | $42,622 |
| Biotissue Holdings Inc. | 19 | $1,944 |
| AbbVie(2 entities) | 62 | $1,683 |
| Alcon | 16 | $1,351 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $865 |
| Sun Pharmaceutical Industries Inc. | 8 | $309 |
| Novartis | 9 | $258 |
| Aerie Pharmaceuticals, Inc. | 7 | $235 |
| Shire North American Group Inc | 5 | $169 |
| Kala Pharmaceuticals, Inc. | 2 | $146 |
| Bausch & Lomb Americas Inc. | 3 | $145 |
| Rxsight Inc | 1 | $128 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $53 |
| Sight Sciences, Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $34 |
| Akorn, Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $31 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| Oyster Point Pharma, Inc. | 2 | $28 |
| Eyevance Pharmaceuticals LLC | 1 | $24 |
| Dompe US, Inc. | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$42,024
- Kahook Dual Blade$42,024
- Clearpath$19,958
- Streamline$19,958
- Via360$14,818
- Prokera$1,478
- AmnioGraft$1,478
- VYZULTA$497
- Wavelight Refractive Suite$362
- Rocklatan$357
- RESTASIS$252
- LOTEMAX SM$249
- Rhopressa$235
- Luxor$145
- AmnioGuard$143
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$128
- Wavelight$127
- XIIDRA$125
- INVELTYS$122
- LUMIGAN$120
How this compares
$50,188 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 134 | $102,089 |
| LumiganBimatoprost | 199 | $66,590 |
| Alphagan PBrimonidine Tartrate | 129 | $32,543 |
| VyzultaLatanoprostene Bunod | 113 | $31,579 |
| CombiganBrimonidine Tartrate/Timolol | 96 | $27,010 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 93 | $22,659 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 331 | $15,865 |
| Travoprost | 116 | $13,926 |
| Prednisolone Acetate | 363 | $11,305 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 73 | $8,806 |
| Ketorolac Tromethamine | 296 | $7,752 |
| Cyclosporine | 39 | $6,512 |
| AzoptBrinzolamide | 17 | $6,173 |
| Brimonidine Tartrate | 73 | $5,790 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $4,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $1,683 | $228,232558 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $145 | $31,579113 claims |
| AlconSimbrinza, Azopt | $1,351 | $28,832110 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $235 | $7,81423 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $865 | $2,49919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.